The US FDA approved Trodelvy (sacituzumab govitecan-hziy) for two first-line indications in unresectable locally advanced or metastatic triple-negative breast cancer (TNBC), marking Gilead Sciences’ (Nasdaq: GILD) most significant regulatory advance for the asset since its initial accelerated approval in 2020. The dual approval — covering monotherapy in patients ineligible for checkpoint inhibitor therapy and a combination regimen with pembrolizumab in PD-L1-expressing tumors — positions Trodelvy earlier in the treatment pathway for a disease subtype with historically limited options.

Trodelvy is a TROP2-directed antibody-drug conjugate that delivers SN-38, the active metabolite of irinotecan, via a hydrolysable linker — enabling targeted cytotoxic payload delivery to TROP2-expressing tumor cells.

The monotherapy approval rested on ASCENT-03 (NCT05382299), a Phase III open-label randomized trial enrolling 558 patients with first-line metastatic TNBC who were not candidates for PD-(L)1 inhibitor therapy. Trodelvy demonstrated a median progression-free survival (PFS) of 9.7 months versus 6.9 months for investigator’s choice chemotherapy (hazard ratio 0.62; p<0.0001). The combination indication was supported by ASCENT-04/KEYNOTE-D19 (NCT05382286), which enrolled 443 PD-L1+ patients; median PFS was 11.2 months with sacituzumab govitecan plus pembrolizumab versus 7.8 months with chemotherapy plus pembrolizumab (hazard ratio 0.65; p=0.0009). Overall survival data remained immature at both analyses.

The approval enters a first-line TNBC landscape that has grown notably competitive within a short period, particularly between ADCs. Daiichi Sankyo and AstraZeneca’s Datroway (datopotamab deruxtecan), another TROP2-directed ADC, received FDA approval for the same checkpoint inhibitor-ineligible first-line TNBC population approximately one month prior. Both agents share a TROP2-targeting mechanism but differ in payload chemistry — Trodelvy uses SN-38 while Datroway employs a DXd topoisomerase I inhibitor — with no direct comparative data yet available. Further pipeline pressure may emerge from sacituzumab tirumotecan, a next-generation TROP2-ADC being developed by Kelun and Merck, which has reported positive Phase III data in first-line TNBC.

This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: https://allsci.com/news/